Updated mSMART consensus guidelines for myeloma--Mayo Clinic Proceedings
Dr. Shaji K Kumar, Associate Professor of Hematology and Medicine at Mayo Clinic in Rochester, MN, discusses updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines. The identification of well-defined and reproducible prognostic factors and introduction of new therapies with unique modes of action and impact on disease outcome have for the first time opened up the opportunity to develop risk-adapted strategies for managing this disease. In the absence of prospectively validated evidence, these consensus guidelines rely on existing evidence (randomized trials, subgroup analyses, and retrospective studies) and are meant to provide a working framework for the management of multiple myeloma. Multiple myeloma, also known as plasma myeloma or Kahler's disease, is a cancer of the plasma cells.